INTERNATIONAL PATENT: EVOLVEIMMUNE THERAPEUTICS, INC., XINGYUE, AN FILES APPLICATION FOR "BISPECIFIC ANTIBODY FUSION MOLECULES TARGETING GPRC5D AND CD3 AND METHODS OF USE THEREOF"

GENEVA, Dec. 24 -- EVOLVEIMMUNE THERAPEUTICS, INC. (23 Business ParkBranford, CT 06405), XINGYUE, An (C/o Evolveimmune Therapeutics, Inc.23 Business ParkBranford, CT 06405) filed a patent application (PCT/US2025/033347) for "BISPECIFIC ANTIBODY FUSION MOLECULES TARGETING GPRC5D AND CD3 AND METHODS OF USE THEREOF" on Jun 12, 2025. With publication no. WO/2025/259877, the details related to the patent application was published on Dec 18, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): PREYER, Martin (43 Weston AveSomerville, MA 02144), MYERS, Jeremy, S. (435 Treat LaneOrange, CT 06477), SARKAR...